Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the protein degradation therapy market?

The market size of protein degradation therapy has witnessed robust growth in recent times. Its expansion is projected to rise from $1.16 billion in 2024 to $1.25 billion in 2025, interpreting a compound annual growth rate (CAGR) of 8.2%. Factors such as the rise in cases of neurodegenerative disorders, the success rate of targeted therapies, increased investments in biotech innovation, the mounting demand for personalized medicine, and a surge in the incidence of conventional therapies’ ineffectiveness against certain diseases have all contributed to the surge in the historic period.

What will be the protein degradation therapy market size in the future?

A substantial expansion of the protein degradation therapy market is anticipated over the forthcoming years, with projections showing a growth to $1.7 billion in 2029 and a 7.9% compound annual growth rate (CAGR). The surge expected in the forecasted period can be accredited to factors such as the increasing number of chronic illnesses, the growth in biotechnological research funding, the escalating demand for targeted therapies, expansion in clinical trials, and favorable regulatory surroundings. Significant shifts anticipated during this period encompass the development of next-generation PROTACs, the combination of artificial intelligence and machine learning, the advent of combination therapies, progress in customized protein degradation therapies, and advancements in oral formulation and drug transportation systems.

Get your protein degradation therapy market report here!

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

What main drivers are fueling expansion in the protein degradation therapy market?

The escalating cancer burden is anticipated to fuel the expansion of the protein degradation therapy market in the near future. Cancer encompasses an array of diseases characterized by the unrestrained growth and spread of anomalous cells within the body. A blend of variables, with the aging populace greatly contributing to the escalating cancer rates. Furthermore, habits such as smoking, unhealthy diet, lack of physical exercise, and increasing obesity rates have heightened the risk of distinct types of cancers. Protein degradation therapy becomes a necessity in cancer treatment as it targets and eradicates the specific proteins that stimulate cancer expansion and survival, and this could possibly surpass the resistance to conventional treatments. For example, as per a report issued by the World Health Organization, an intergovernmental organization headquartered in Switzerland, in February 2024, over 35 million fresh cancer cases are forecasted for 2050, signifying a 77% upsurge from the projected 20 million cases in 2022. Furthermore, countries with high Human Development Index (HDI) are likely to witness the biggest surge in sheer numbers, with an excess of 4.8 million new cases projected in 2050 compared to the 2022 predictions. Therefore, the escalating cancer burden is fueling the protein degradation therapy market’s growth.

What key areas define the segmentation of the global protein degradation therapy market?

The protein degradation therapy market covered in this report is segmented –

1) By Type: Bavdegalutamide (ARV – 110); Vepdegestrant (ARV – 471); Other Types

2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications

3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes

Subsegment:

1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy

2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp

Who are the dominant players expanding their reach in the protein degradation therapy market?

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

How are evolving market trends shaping protein degradation therapy Strategies?

Prominent enterprises in the protein degradation therapy market are forming strategic alliances to conjure innovative treatments, harness complementary skills, pool resources, and expedite the discovery and development of new drug candidates that target proteins causing diseases. These strategic collaborations involve firms exploiting each other’s robustness and resources for reciprocal benefits and shared triumph. For example, in June 2022, Merck KGaA, a German science and technology company, joined forces with Proxygen, a biotechnology company based in Austria, in an important multi-year research collaboration and licensing agreement to develop molecular glue degraders. Valued at up to $2.55 billion, this partnership encompasses an upfront payment and potential milestone payments contingent on achieving certain research, development, and commercial milestones. The partnership will harness Proxygen’s proficiency in molecular glue degraders, intended to selectively reconfigure cellular mechanisms to eliminate disease-causing proteins. This strategy targets proteins that are often deemed “undruggable” by conventional methods, thereby presenting new possibilities for therapeutic advancement.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20603

Which regions are emerging as leaders in the protein degradation therapy market?

North America was the largest region in the protein degradation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Home Infusion Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report

CAR-T Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Aromatherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: